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Abstract
Background: During the last decade online interventions have emerged as a promising approach for patients with
mild/moderate depressive symptoms, reaching at large populations and representing cost-effective alternatives. The
main objective of this double-blind, randomized controlled trial is to examine the efficacy of an internet-based self-
management tool (iFightDepression) for mild to moderate depression as an add-on to treatment as usual (TAU)
versus internet-based psychoeducation plus TAU.
Methods: A total of 310 participants with major depression disorder (MDD) will be recruited at four different
mental-health facilities in Spain. Participants will be randomly allocated to one of two study arms: iFightDepression
(iFD) tool + TAU vs. internet-based psychoeducation + TAU. Both interventions last for 8 weeks and there is a
12 weeks follow up. The primary outcome measure is changes in depressive symptoms assessed with the Hamilton
Depression Rating Scale. Additionally, pre-post interventions assessments will include socio-demographic data, a
brief medical and clinical history and self-reported measures of depressive symptoms, quality of life, functional
impairments and satisfaction with the iFD tool.
Discussion: iFightDepression is an easy-prescribed tool that could increase the efficacy of conventional treatment
and potentially reach untreated patients, shortening waiting lists to receive psychological treatment. Confirming the
efficacy of the iFD internet-based self-management tool as an add-on treatment for individuals with mild to
moderate depression will be clinically-relevant.
Trial registration: Registration number NCT02312583. Clinicaltrials.gov. December 4, 2014.
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Background
According to the World Health Organization (WHO) pre-
dictions, by 2030 depression will be the leading cause of
disease burden globally. Depression is not only associated
with disability and with enormous individual impairments,
but also it entails high economic cost for society [1, 2].
Depression is a recurrent disorder, meaning that one in-
dividual will suffer an average of four depressive episodes
during his/her life [3]. Establishing an effective treatment
at the early stages of the disease is fundamental for the
successful prognosis of the disorder [4]. Although several
treatment options have been developed for depression, a
large proportion of individuals do not have access to these
treatments and some of them remain untreated [5]. Fur-
thermore, contrary to what is suggested in international
guidelines for the management of mild and moderate de-
pression symptoms, the majority of General Practitioners
(GPs) tend to prescribe antidepressant medications [6, 7].
In this context, online interventions appear as promising
treatment approaches that can reach a large majority of
patients [8, 9], while at the same time, representing cost-
effective alternatives [10]. For clients, internet-based pro-
grams offer some advantages. These include: anonymity,
avoiding the stigma associated with seeing a therapist and
the option to do the treatment at any time and place, at
the client’s own pace, for example, at home [11, 12]. Ther-
apist involvement depends on the intervention, but in
general, most programs aim at decreasing the therapist
workload. Most internet-based treatments are framed in
cognitive behavioral therapy (CBT) and are developed to
treat individuals with mild to moderate depressive symp-
toms that are usually visited in primary care settings. In a
meta-analysis of randomized-controlled trials comparing
the effects of guided self-help and face-to-face psychother-
apies, it was concluded that both interventions have com-
parable effects. Thus, recommending the implementation
of guided self-help interventions in routine care [13].
In the context of the European project Preventing De-
pression and Improving Awareness through Networking in
the European Union (PREDI-NU) [14], the European Alli-
ance Against Depression (EAAD) created the iFightDepres-
sion (iFD) tool. The EAAD is a consortium of different
countries around the world that use an evidence-based
approach for improving care of depressed persons and pre-
vent suicidal behavior [15]. IFD is an internet-based self-
management tool for moderate to mild depression designed
as a complementary intervention to standard care. IFD is
based on cognitive behavioral therapy and structured in
seven different modules.
Study objectives
The aim of this double blind, randomized controlled
trial (RCT) is to examine the efficacy of the iFightDe-
pression as an add-on to treatment as usual (TAU) for
patients with mild to moderate depressive symptoms
versus internet-based psychoeducation plus TAU. The
primary outcome measure will be changes in depressive
symptoms as measured with the Hamilton Depression
Rating Scale [16]. Secondly, we aim at examining the ef-
fects of this intervention on other variables including
quality of life and functioning.
Methods
Design
We designed an 8-week, double-blind, randomized con-
trolled trial, with two treatment arms: iFightDepression
tool + TAU and internet-based psychoeducation + TAU.
Participants will be randomly allocated (1:1) after the
first assessment visit. Randomization will be performed
electronically by an independent study researcher. Par-
ticipants in both treatment arms will be followed via
internet during a 12-week period.
Study participants
A total of 310 participants with major depressive dis-
order (MDD) diagnosis will be included in the study.
Diagnosis will be made according DSM-IV-TR criteria
and participants will be recruited from different mental
health services (i.e., Red de Salud Mental de Guipúzkoa,
Hospital del Mar, Hospital de la Santa Creu i Sant Pau,
Hospital Parc Taulí and Hospital Universitario de la
Princesa) and primary care facilities in their catchment
areas. Sample size was established in order to detect an
effect size of d = 0.2 with 95% power (SE = 0.5) and as-
suming a conservative correlation coefficient between
pre-post measures of 0.5 and a drop-out of 20%. Sample
size was calculated using G*Power 3.1.7 software.
Individuals meeting the following criteria will be eli-
gible: 1) Participants of both genders 18 years old and
older, 2) MDD diagnosis according to DSM-IV-TR cri-
teria with mild-moderate symptoms according to the
CGI-severity (scores ≤4), 3) minimum knowledge of
internet use and availability of an internet device (tablet,
computer, smartphone) and 3) given written informed
consent. Exclusion criteria are: 1) suicidal ideation
assessed by the HDRS and/or clinical interview, 2)
psychotic symptoms related or not related to a mood
disorder, 3) severe comorbidity axis I and axis II diagno-
sis, 4) currently receiving standard face-to-face CBT.
Procedure
Eligible participants will be identified through the different
sites by a case manager, mainly, by the participant’s gen-
eral practitioner. However, other professionals (i.e., psych-
iatrist, psychologist or community mental health nurses)
with experience in the assessment and diagnosis of de-
pression would be also able to refer participants to the
study. These professionals will verify inclusion/exclusion
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criteria and will inform patients about the study. Partici-
pants who confirm their interest in participating, will be
contacted by phone within 1 week to schedule the first as-
sessment visit (face-to-face). Each site will designate a
highly trained psychologist who will conduct the first face-
to-face visit in order to confirm that participants met
inclusion/exclusion criteria and to obtain the written in-
formed consent. Participant’s assessment will be recorded
in the electronic Case Report Form (e-CRF). In this as-
sessment visit, and regardless of the treatment arm the pa-
tient will be assigned to, the second face-to-face
assessment visit (week 8) will be booked. Randomization
to one of the two conditions (i.e., iFightDepression tool +
TAU or internet-based psychoeducation + TAU) will be
electronically performed by the e-CRF once the patient
data is introduced. The researcher who conducts assess-
ment visits will remain blind to participant’s allocation.
After the first visit, participants in both arms will received
an email with instructions to be followed. The interven-
tion group will receive instructions to create an ac-
count and to work within the iFD tool. In addition,
the intervention group will receive a telephone call to
make sure that participants activated successfully their
user accounts. Then, they will be contacted bi-weekly
by a mental health professional (specialized nurse or
psychologist), to work through the material and to
provide technical support). During the 8 weeks of the
trail all participants will be follow-up by e-mail in
order to complete the PHQ-9 and RDQ. Participants
will have to complete the PHQ-9 and the RDQ again
at week 12. The study protocol was developed in ac-
cordance with the SPIRIT (Standard Protocol Items:
Recommendations for Interventional Trials) guidelines
[17]. A flowchart of participants is shown in Fig. 1.
Ethical issues
All participants will be provided with an overview of
the study’s aims and characteristics summarized in the
Participants Information Sheet (PIS). The voluntarily
character of the study will be specified, indicating that
withdrawal from the study is permitted at any time,
without interfering with the usual treatment. Written
informed consent will be obtained from all participants
before proceeding with randomization. The study will
be performed according to the ethical standards stated
in the Declaration of Helsinki and its subsequent up-
dates. The Ethics Committee Board of the Parc de Salut
Mar approved the study protocol in October 2014. Data
registered in the e-CRF will be coded as to ensure the
confidentiality of participant’s identity. The access to
the code key will be restricted to the principal investi-
gator of the study, and will be stored separately in a
safe place.
Description of the interventions
Intervention group (iFightDepression tool + TAU)
IFightDepression (https://tool.ifightdepression.com) is an
internet-based self-management tool designed as a com-
plementary intervention to standard care for patients
with mild/moderate symptoms of depression. IFD was
created by the European Alliance against Depression
(EAAD) and is based in cognitive behavioral therapy
(CBT). The IDF tool is structured in seven core modules
(workshops) relating to behavioral activation (monitor-
ing and planning daily activities), cognitive restructuring
(identifying and changing unhelpful thoughts), sleep
regulation, mood monitoring, and healthy lifestyle
habits. Each module consists of written information, as-
sociated tasks and corresponding worksheets to consoli-
date learning and promote self-monitoring. A guide on
how to complete the worksheets is provided in each
module. Worksheets can be printed or completed on-
line and are saved in the participants profile for latter
review. Patients are encouraged to work with the work-
sheets for an entire week so the whole content of the
program is developed to be completed in 8 weeks. An
outline of each module can be found in Table 1. In
addition, the tool has a “Frequently asked questions
(FAQ)” section and a section “About IDF”, in which par-
ticipants can find information regarding the causes of
depression, the use of the tool, and further reading on
cognitive behavioral therapy.
For the purpose of this study and to facilitate the re-
cruitment, the IFD tool is available in three languages:
Spanish, Catalan and Basque, and patients are allowed to
choose among versions according to their language
preferences. Participants can access the PHQ-9 at any
time, to assess their depression symptoms. A guide for
interpreting the PHQ-9 scores is provided. If the patient
responds positively to the item regarding suicide (i.e.,
“Thoughts that you would be better off dead or of hurt-
ing yourself in some way”) a message recommending
seeking for emergency care will appear on the top of the
screen. In addition, emergency contacts for Spain are
listed on the website. The use of IDF tool is complemen-
tary to TAU which consists of monthly visits with the GP
and pharmacological treatment with an ISRSS if needed.
Active control group (internet-based psychoeducation + TAU)
Internet-based psychoeducation consists of a webpage
containing information about MDD and healthy habits.
This webpage (www.ifightdepression.com) was also de-
signed by the EAAD consortium, and unlike the tool,
workshops and tasks are lacking. The psychoeducative
content of this website is restricted to information re-
garding healthy habits (healthy eating, physical activity,
positive social contact and daily organization). In
addition, information on the following topics is included:
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what is depression, signs and symptoms, diagnosing de-
pression, subtypes of depression, brain function in de-
pression, causes and an overview of depressions
treatment (both pharmacological and psychological).
Participants on this condition can also complete the on-
line PHQ-9. This is an open-access webpage (i.e., a user-
name and password are not required). Participants
allocated to this condition will receive an e-mail with
the page link and will be instructed to navigate freely
throughout their content. As in the intervention group,
TAU consists of monthly visits to the GP together with
pharmacological treatment (if needed).
Study measures
Different types of variables will be collected (see Table 2)
including socio-demographic characteristics of the sample
(i.e., gender, age, ethnic group, marital status, living
arrangements, educational level, employment status and
annual income) and an exhaustive clinical history [i.e., age
at MDD onset, number of previous MDD episodes, days
in inpatient hospitalization (if applied), axis I and axis II
diagnosis, and current pharmacological treatment].
Diagnostic variables
Depression symptoms and suicide risk will be assessed
using the specific sections of the Mini-International
Neuropsychiatric Interview (MINI) [18], a short diagnos-
tic structured interview. In addition, an ad hoc question-
naire was created for accounting for sociodemographic
and clinical data.
Primary outcome measure
The Hamilton Depression Rating Scale (HDRS) [16] will be
the primary outcome measure. This is a clinician-
Fig. 1 Flowchart of participants
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administered scale. Each item on the questionnaire is
scored on a 3- or 5-point scale, depending on the item.
Secondary outcome measures
The following instruments will be used to assess other
outcomes:
Patient Health Questionnaire (PHQ-9) [19] is an in-
strument for screening severity of depression according
to DSM-IV-TR criteria. The tool rates the frequency of
the symptoms during the last 2 weeks using a scale from
0 (not at all) to 3 (nearly every day).
Clinical Global Impression Severity and Improvement
(CGI-S and CGI-I; [20]. The CGI-S scale would be used to
evaluate the clinical severity of the participant in a scale
from 1 to 7 (“normal, not ill at all” to “extremely ill”). Both
a patient-rated version and a clinician-rated version will
be used. The CGI-Improvement (CGI-I) will be also used,
in order to evaluate the improvement between the base-
line visit and the post-intervention assessment (from
1:“very much improved” to 7:“very much worse”).
Remission from Depression Questionnaire (RDQ; [21] is
a self-reported instrument developed from a patient-
centered perspective, including the aspects that they con-
sidered as part of depression remission. The RDQ evalu-
ates depressive symptoms, positive mental health and
satisfaction with life, well-being and social functioning.
EuroQol-5D questionnaire (EQ-5D-5 [22] is a widely
used measure of health-related quality of life. The
Table 2 Measures used by study period
Measure Baseline assessments
(Face to face)
Week 2
(Online)
Week 4
(Online)
Week 6
(Online)
Post-intervention assessment
(Face to face)
12 weeks FU
(online)
Demographic information
(gender, age, marital status, etc.)
x
Medical/Psychiatric History x x
MINI (depression and suicide risk
sections)
x x
Primary outcome measure:
-HDRS x x
Secondary outcome measure:
-PHQ-9 x x x x x x
-CGI-S x
-RDQ x x x x x x
-EuroQol-5D x x
-FAST x x
-Ad hoc satisfaction
Questionnaire
x
Note: MINI Mine-international Neuropsychiatric Interview, HDRS Hamilton Depression Rating Scale, PHQ-9 Patient health Questionnaire, CGI-S Clinical Global
Impression-Severity, CGI-I Clinical Global Impression-Improvement, RDQ Remission from Depression Questionnaire, FAST Functioning Assessment Short Test
Table 1 Content outline for iFightDepression tool-intervention group
Module Content/Aim Worksheet
1 thinking, feeling and doing Recognizing the relationship between thoughts,
feelings and behavior.
Activity Monitoring
2 Sleep depression Gaining awareness of the influence of sleep on
depression.
Sleep Diary
3 Planning and doing enjoyable things Building up positive activities in the daily life. Planning Ahead
4 Getting things done Developing skills for problem solving and to get
things done.
Getting things done
5 Identifying negative thoughts Understanding the link between thoughts and
mood, and learning how to recognize cognitive
distortions.
Events, Thoughts and Reactions
6 Changing negative thoughts Learning how to challenge negative thoughts and
how to replace them with more positive alternatives.
Thought Challenge
7 Feel better all around: Healthy Lifestyle Giving tips for developing a healthy lifestyle in general.
Including healthy diet, exercise and sleep.
Sleep Worry Planner
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instrument is composed of two parts. Part one provides
a self-reported description of health problems classified
into five dimensions and patients have to rate the sever-
ity corresponding to each dimension in a 5-point scale.
Part two consists of a 10 cm line Visual Analogue Scale
(VAS) corresponding to the current state of subject’s
health. The lowest extreme of this scale (0) corresponds
to the worst imaginable health state, while the highest
extreme (100) refers to the best imaginable health state.
Functioning Assessment Short Test FAST [23] is a
brief instrument developed to assess the main function-
ing problems experienced by patients. It comprises 24
items assessing impairment or disability in six areas of
functioning: autonomy, occupational functioning, cogni-
tive functioning, financial issues, interpersonal relation-
ships and leisure time. Each item is rated on a 4-point
scale (0 = no difficulty, 1 = mild difficulty, 2 = moderate
difficulty and 3 = severe difficulty).
An ad hoc satisfaction questionnaire was created for
participants allocated to the intervention group.
Statistical analysis plan
SPSS v22.0 will be used for statistical analyses. Primary
analyses will be conducted on the Intention-To-Treat
(ITT) sample. Missing data will be inspected and han-
dled via full information maximum likelihood (FIML) or
multiple imputations (MI) as appropriate.
The primary outcome is change in HDRS scores from
baseline to post-treatment (8 weeks). For primary and
secondary outcome measures, repeated measures ANO-
VAs will be computed to examine pre-post treatment
differences between groups.
Discussion
The present study aims at evaluating the efficacy of an
internet-based self-management tool for moderate to mild
depression compared with internet-based psychoeduca-
tion. Confirming the efficacy of the iFightDepression tool
will entail important implications. As IFD could be easily
prescribed it could potentially reach patients that usually
remain untreated or have to wait for long-periods to re-
ceive psychological treatment. In addition, the availability
of the both interventions in three different languages
(Spanish, Catalan and Basque) aims at facilitating partici-
pant’s adherence. A strength of our study is that the re-
cruitment will mainly take place in general practices, were
patients with mild to moderate depression symptoms are
often treated.
The risk of dropout constitutes one of the potential
major obstacles of our study. We’ve tried to mitigate this
by expanding our recruitment area to public health-care
facilities located in three large areas of Spain (Catalonia,
Madrid and Basque Country) and by providing specific
language versions of the iFD tool and the psychoeducation
web-page. As commented before, the design of our study
privileges a naturalistic approach and therefore, partici-
pants will be recruited from primary care facilities in
which most patients with mild/moderate symptoms of de-
pression are visited and participants with concomitant ant
depressive medication will be allowed in the study. Con-
sidering that the effects of the concomitant medication
may impact our findings, a sub-analysis evaluating the po-
tential effects of antidepressant will be conducted and par-
ticipants will be excluded from the study if drastic
changes in their medication took place during the study
period.
In summary, the present study aims to provide evi-
dence in regards to iFD tool as an add-on approach for
individuals presenting mild to moderate symptoms of
depression. Counting on a tool like iFD will facilitate its
use in the public health care system, representing a
treatment approach that can potentially reach a large
amount of patients avoiding long waiting lists.
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